Connect with us

Medicinal

Apollon Formularies cannabis products effective at killing prostate cancer

The Apollon medical cannabis formulations are an opportunity for more men to have their prostate cancer treated. 

Published

on

Apollon Formularies cannabis products effective at killing prostate cancer

Preclinical results have shown that Apollon Formularies cannabis formulations are effective at fighting prostate cancer.

Trading on the Aquis Stock Exchange, UK-based pharmaceutical company Apollon Formularies has carried out third party independent testing of its medical cannabis formulations, which were found to be effective in killing hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures. 

The medical cannabis formulations were developed by Apollon Formularies Jamaica Limited and testing was carried out by independent testing laboratory, BIOENSIS. 

Apollon intends to immediately make the formulations available to licensed Jamaican physicians with experience in prescribing Apollon products, which will enable them to begin treating prostate cancer patients in Jamaica.

Positive pre clinical results

Laboratory testing results demonstrated that the formulations were effective in killing living hormone-sensitive and hormone-resistant prostate cancer cells directly, killing nearly 100% of the prostate cancer cells.

Previously, the formulations have also demonstrated success in killing HER2+ breast cancer cells and triple-negative breast cancer cells.

Stephen Barnhill, MD and CEO of Apollon, commented: “Cannabinoids have been seen to exert ‘anti-tumour’ effects by a number of different means, including killing cancer cells directly as well as inhibiting transformed cell growth and tumour metastasis.

“We are extremely excited that our proprietary medical cannabis formulations have been validated via independent laboratory testing to kill both hormone-sensitive and hormone-resistant prostate cancer cells in 3D cell cultures via direct cytotoxicity.”

“These remarkable results demonstrating the ability of the Apollon formulations to directly kill nearly 100% of prostate cancer cells in 3D cell culture provide us independent scientific evidence of the success of these products in pre-clinical testing,” added Dr Herbert Fritsche, Chief Science Officer of Apollon, and former Professor and Director of Clinical Chemistry at the University of Texas, MD Anderson Cancer Center.

“Pursuant to the Research & Development and the Retail-Therapeutic medical cannabis licences issued to Apollon Jamaica by the Jamaican Cannabis Licensing Authority (CLA), we intend to make these formulations immediately available to licensed Jamaican physicians experienced in prescribing Apollon products, allowing them to begin immediately treating patients who have prostate cancer in Jamaica where the companies’ formulations are currently available by physician prescription. This will allow us to supplement these impressive laboratory results with clinical data from the treatment of human patients.”

A cost-effective prostate cancer treatment

Chairman and CEO of Apollon Jamaica, Paul Burke, highlighted that the formulations are expected to be a more cost-effective treatment for prostate cancer.

“These Apollon formulation test results on prostate cancer and the plan to immediately begin treatments in Jamaica are extremely exciting developments for Jamaican men, in part, because traditional chemotherapy, radiation, and surgery cancer treatment protocols are expensive and require a great deal of infrastructure,” said Burke. 

“As a result, many men in Jamaica and worldwide have gone without treatment or with only limited treatment. The Apollon medical cannabis formulations are expected to be comparatively much less expensive, providing an opportunity for more men to have their prostate cancer treated. 

“I look forward to bringing these formulations to market as quickly as possible and in a manner that allows Jamaican men with prostate cancer, as well as men traveling from international locations to Jamaica as medical tourists for our treatment, to have access to high quality complementary and alternative medical care.”

The testing occurred as a part of a Joint Testing Agreement between the parties and was authorised in accordance with Apollon Jamaica’s Research & Development licence issued by the Jamaican government’s Cannabis Licensing Authority (CLA).

 

Medicinal

New agreement to fund Phase II trials for cannabis glaucoma treatment

Emerald Health Therapeutics has signed an agreement with Skye Bioscience.

Published

on

New agreement to fund Phase II trials for cannabis glaucoma treatment
Home » News » Medicinal » Apollon Formularies cannabis products effective at killing prostate cancer

A new agreement between Emerald Health Therapeutics and Skye Bioscience will enable Phase II studies exploring the use of Skye’s proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma.

Glaucoma is the globe’s leading cause of irreversible blindness – affecting nearly 80 million people across the globe – and has no cure.

Skye Bioscience‘s lead programme, SBI-100 Ophthalmic Emulsion, is focused on treating glaucoma. SBI-100 OE is designed to improve the ocular solubility and permeability of a cannabinoid receptor-type 1 agonist. 

So far, preclinical studies have demonstrated that topical application of the nanoemulsion results in enhanced therapeutic efficacy and duration of response, allowing for a potentially once-a-day application to the eye. The results showed superior lowering of intraocular pressure, a key risk factor in disease progression.

Read more: Positive results for cannabinoid targeting multi-billion pain market

Under the new agreement, which would see Skye acquire all of the issued and outstanding shares of Emerald in a share-for-share-transaction, Skye expects to have funding for a Phase II study which is expected to begin in the fourth quarter of 2022, following a Phase I study beginning in the second quarter of 2022.

Chair of the Skye’s special committee and president, CEO and board member of Invectys, Inc., Praveen Tyle, Ph.D., commented: “Skye’s proposed acquisition of Emerald stands to strengthen its balance sheet and ability to advance its well-positioned technology and development platform that has generated promising preclinical data in the past year and a half. 

“Despite the constraints of Covid on all facets of the life science industry, Skye has completed the preclinical preparation necessary to launch its first-in-human study of its lead drug, SBI-100 OE, in the second quarter of 2022. 

Read more: New partnership aims to transform global phytomedicine sector

“We expect regulatory approval to start our Phase I study and begin enrolling patients shortly. The transaction with Emerald is expected to provide funding into 2023 and, importantly, for our planned Phase II study starting in the fourth quarter of 2022.

“The shortcomings of today’s glaucoma drugs are significant for patients. Today we are focused on clinically validating what could potentially be an advantageous new class of therapeutic drug for glaucoma. 

“With this in mind, we are actively designing a Phase II efficacy study to deliver potentially meaningful data, yet optimised to minimise time and cost. We believe we can see preliminary data from this study in 2023, and the nature of this data could be transformational from a validation and value creation perspective. 

“Securing the capital to achieve these goals is vital. We believe that acquiring Emerald and its cash and non-cash assets would provide a more favourable capital cost for our shareholders compared to other alternatives in light of current investment market conditions. 

“In addition, Emerald possesses a research and development facility in the greater Vancouver area licensed to undertake cannabinoid-related research under applicable Canadian law, which could be beneficial to Skye as we continue to progress our R&D efforts.”

Chair of the board’s Special Committee of Emerald Health Therapeutics, Bobby Rai, commented: “We are excited to present this opportunity with Skye to our shareholders. Since announcing the strategic pivot of Emerald last November, we have been working to wind down our past operations, monetise our non-cash assets, and apply our capital to a new investment opportunity. We have searched for a company with differentiated positioning and a pedigree of expertise and experience. We believe we have found it in Skye Bioscience.

“Emerald has always recognised the therapeutic potential of cannabinoids based on our experience with the body’s endocannabinoid system and its modulating and balancing activities in the body. We also recognise that the goal to clinically and commercially capitalise on the potential therapeutic benefits of cannabinoid-derived drugs may benefit from advanced technology and drug products with mechanisms of action or formulations enhanced to realise effects superior to not only natural cannabinoids but to existing approved classes of drugs and those under development. 

“The beauty of this situation is that the underlying cannabinoid that Skye is working with has previously been shown through prior third-party research to have promising potential. And Skye’s recent preclinical work has shown improved delivery of the underlying cannabinoid to the back of the eye and notable effects in reducing intraocular pressure, which is a key risk factor of glaucoma.

“Skye Bioscience has proprietary technology, R&D initiatives to expand its therapeutic capabilities, a strong focus on IP, along with a management team, board, and advisory board with many decades of experience in pharmaceutical drug development and clinical practice, notably in ophthalmology and in fundamental cannabinoid research. This company is uniquely positioned to capitalise on the substantially untapped opportunities represented by the intersection of cannabinoids with modern science and traditional drug development.

“We believe this is an excellent opportunity for Emerald shareholders to potentially benefit from a new class of cannabinoid-derivative drug candidates.”

Continue Reading

Markets and industry

Apollon Formularies purchases four patents from Aion Therapeutic

Published

on

apollon acquires intellectual property

Apollon Formularies has announced the acquisition of four patents previously owned by AI Pharmaceuticals, covering a number of treatments for cancers and inflammation using cannabis and mushroom compositions.

Apollon Formularies plc, a UK based international pharmaceutical company has acquired intellectual property from AI Pharmaceuticals Ltd, a wholly-owned Jamaican subsidiary of Aion in what Apollon is calling a “win-win” for both companies. Under the terms of the Agreement, Apollon will acquire four patents and all associated supporting data including the pre-clinical testing results from BIOENSIS.

The patents include: ‘Compositions and Methods for Treatment of Cancers’, ‘Compositions and Methods for Treatment of Inflammation, ‘Methods for Treatment of Human Cancers using Mushroom Compositions’ and ‘Methods for Treatment of Human Cancers using Cannabis Compositions’.

In a statement, Stephen Barnhill, MD, Chairman and CEO of Apollon Formularies said: “This intellectual property acquisition is a win-win for both companies. Apollon’s Jamaican affiliate, Apollon Formularies Jamaica Limited, has Cannabis Licensing Authority (CLA) issued medical cannabis licenses for processing, retail therapeutic sales, and research and development which allows performing human clinical trials with approval of the Ministry of Health (MOH) and cultivation. Apollon’s CLA licenses also currently allow the export of these products from Jamaica to countries globally allowing legal import.

Dr. Barnhill is also the Executive Chairman of Aion and serves as a director and executive officer of AI Pharmaceuticals.

Apollon, which is trading on the Aquis Stock Exchange, has purchased the patents from Aion via a cash payment of £95,957.18 and the issuing of 4,348,679 ordinary shares in the company. These shares will be subject to a complete trading restriction for a period of six months from the date of the stock transfer. After the six month restriction period, twenty percent of such stock will become eligible for trading and an additional twenty percent will be tradable at the end of each following three-month period, with all trading restrictions being fully removed at the end of eighteen months.

In addition to the cash payment and Apollon shares, Apollon will pay to Aion a royalty fee of four percent of Net Revenues on all products produced and sold globally that are derived from or based on the purchased intellectual property assets. The royalty fee shall be due from Apollon on a quarterly basis after the first commercial product sales.

“Apollon has a state-of-the art, high volume processing and manufacturing facility in Jamaica allowing production of these products. Apollon intends to immediately make these medical cannabis and medicinal mushroom products available at Apollon’s International Cancer and Chronic Pain Institute in Kingston, Jamaica and at our CLA-licensed dispensary in Negril, Jamaica, as well as initiating human clinical trials to validate the successful results seen in the pre-clinical testing.”

AI Pharmaceuticals and Apollon Formularies Jamaica announced in May last year that the two companies had made arrangements for the testing of their respective formulations and products independently and jointly. BIOENSIS, an independent pre-clinical predictive pharmaceutical testing laboratory, previously evaluated the effect of mushroom and cannabis formulations on multiple cancer cell lines in 3D cell cultures.

Continue Reading

Medicinal

New partnership aims to transform global phytomedicine sector

HempStreet and MGC Pharmaceuticals have teamed up to increase access to phytopharmaceutical medicines for patients.

Published

on

New partnership aims to transform global phytomedicine sector
Home » News » Medicinal » Apollon Formularies cannabis products effective at killing prostate cancer

India’s first medical cannabis “research to retail” venture, HempStreet, and Europe’s biopharma and phytomedicine specialist, MGC Pharmaceuticals, have entered into a partnership that will see the pair combine research and development as well as distribution strengths to improve quality of life.

UK-based MGC Pharma has been working on polyherbal formulations based on cannabis and other phytopharmaceuticals. Through this new partnership MGC Pharma will leverage HempStreet’s extensive distribution reach and key institutional partnerships to bring Indian patients access to its medicines.

Read more: MGC Pharma initiates study for long-COVID

The partnership will also help to accelerate HempStreet’s upcoming venture, the transdermal delivery technology for cannabinoids, to launch in markets beyond Asia with the help of MGC Pharma’s distribution network in Australia, UK, Brazil and Ireland.

Co-founder of HempStreet, Abhishek Mohan, commented: “We are very excited to work with Roby and the team at MGC Pharma, bringing cutting-edge, scientifically-validated phytopharmaceutical medicines to tackle mass ailments in India and beyond. 

Read more: MGC Pharmaceuticals cannabis epilepsy treatment now free to Irish patients

“In particular, CimetrA, which has shown a 100 per cent success rate in Phase II clinical trials in India, will be an important product just on account of the fact that an estimated 15 million individuals are experiencing some sort of post-Covid-19/Long-Covid symptoms.”

MGC Pharma has stated that CimetrA – made of artemisinin, curcumin, and boswellia serrata – is effective in arresting cytokine storms associated with Covid-19. There are currently over 15 million individuals, approximately 30 per cent of all Covid-19 recoverees in India, said to be experiencing some form of post- or long-Covid related symptoms.

Co-founder, MGC Pharma, Roby Zomer, added: “Entry into significant global markets such as India is paramount to MGC Pharma’s agenda, advancing phytomedicine adoption globally. 

“India has a long-established and government-supported Ayurvedic healthcare system, and working with HempStreet to facilitate access to our proprietary phytomedicines such as CimetrA and CannEpil and the new formulations on the pipeline, is crucial to gaining a foothold in this market.”

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts